RecruitingNCT05713994

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ze-yang Ding, MD
Principal Investigator
Wanguang Zhang, M.D., M.D
Tongji Hospital
Intervention
HAIC(procedure)
Enrollment
300 target
Eligibility
18 years · All sexes
Timeline
20202025

Study locations (2)

Collaborators

Chinese Cooperative Group of Liver Cancer · Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province · Haplox Biotechnology Co., Ltd. · Geneplus-Beijing Co. Ltd. · The Second Affiliated Hospital of Fujian Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05713994 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials